Company: SXTPW
Filing Date: 2025-06-06
Form Type: DRS
Source: 0001213900-25-052232
Chunk: 32

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-06-06
Form: DRS
Chunk 32
---
 which the Company sold, in a registered direct offering an aggregate of 204,312 shares (the “January
2025 Shares”) of common stock at a purchase price of $5.105 per share in a registered direct offering priced at-the-market under
the rules of Nasdaq. The January 2025 Offering closed on January 30, 2025.

<div align='center'>12</div>

The January 2025 Shares were offered pursuant
to a “shelf” registration statement on Form S-3 (Registration No. 333-280796), which was declared effective by the SEC on
July 18, 2024 as supplemented by a prospectus supplement dated January 28, 2025, filed with the SEC on January 30, 2025, and accompanying
base prospectus, pursuant to Rule 424(b)(5) promulgated under the Securities Act.

In a concurrent private placement, the Company
also issued to the January 2025 Purchasers unregistered warrants (the “January 2025 Warrants”) to purchase up to an aggregate
of 408,621 shares of common stock at an exercise price of $3.855 per share, subject to certain adjustments. The January 2025 Common Warrants
are exercisable upon issuance and expire twenty-four months from the date of issuance.

The Selling Shareholder S-1 registered the January
2025 Shares and the shares underlying the January 2025 Warrants.

The issuance of the January 2025 Warrants pursuant
to the January 2025 Securities Purchase Agreement and issuance of the January 2025 Placement Agent Warrants (defined below) were made
pursuant to the exemption from the registration requirements under the Securities Act of 1933, as amended (the “Securities Act”),
available to the Company under Section 4(a)(2) promulgated thereunder and Rule 506 of Regulation D promulgated under the Securities Act
due to the fact the offering of the January 2025 Warrants and the January 2025 Placement Agent Warrants thereunder did not involve a public
offering of securities.

The Company paid Wainwright, the placement agent
in the February 2025 Offering, a cash transaction fee equal to 7.5% of the aggregate gross cash proceeds in the offering and a management
fee equal to 1.0% of the aggregate gross cash proceeds in the offering. In addition, the Company paid for certain non-accountable expenses